An 8 Week Randomized, Placebo Controlled, Double-blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules in Patients of African Descent With Chronic Obstructive Pulmonary Disease

  • NCT00106821
  • PHASE4
  • INTERVENTIONAL

Last updated: 2013-11-01

Purpose of  Trial

The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.


This study is for people with

Pulmonary Disease, Chronic Obstructive


Interventions being studied

Tiotropium Bromide Inhalation Powder

Inclusion Criteria:

* Male or female of African descent

* 40 years of age or older

* Diagnosis of COPD

* History of smoking at least one pack per day for at least 10 years

* Currently experiencing shortness of breath at least with exertion

Exclusion Criteria:

* Asthma

* Recent myocardial infarction or hospitalization for congestive heart failure

Register to Save
ELIGIBILITY

Gender: ALL

Age: 40+

Healthy Volunteers: No

19 Locations
Birmingham

Boehringer Ingelheim Investigational Site


Alabama, United States
Birmingham

Cooper Green Hospital


Alabama, United States
Birmingham

University of Alabama at Birmingham


Alabama, United States
Los Angeles

David Geffen School of Medicine


California, United States
Sepulveda

VA Greater Los angeles Health Care Systems


California, United States
Waterbury

Boehringer Ingelheim Investigational Site


Connecticut, United States
WEst Haven

Yale Univ. Pulmonary and Critical Care Medicine


Connecticut, United States
Panama City

Emerald Coast Research Associates


Florida, United States
St. Petersberg

Bay Pines V. A. Medical Center


Florida, United States
New Orleans

Louisiana State University School of Medicine


Louisiana, United States
Shreveport

LSU MC-Sheveport


Louisiana, United States
Bronx

Bronx VA Medical Center


New York, United States
Greenville

Brody School of Medicine, East Carolina University


North Carolina, United States
Philadelphia

Boehringer Ingelheim Investigational Site


Pennsylvania, United States
Philadelphia

Temple University Hospital


Pennsylvania, United States
Charleston

Boehringer Ingelheim Investigational Site


South Carolina, United States
Spartanburg

Spartanburg Medical Research


South Carolina, United States
Houston

Attention: Amir Sharafkhaneh, M.D.


Texas, United States
Houston

VAMC Houston


Texas, United States
Primary Contact(s)

Boehringer Ingelheim

Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at ClinicalTrials.gov

Back to Results New Search